Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 2.86% is 75% below its 5-year average of 11.22%, near the low end of its 5-year range (2.86%–42.42%).
As of the fiscal period ended Friday, October 31, 2025. 39.15% below its 12-month average of 4.70%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
2.86%
RETURN ON EQUITY (ROE) AVG TTM
4.70%
RETURN ON EQUITY (ROE) AVG 3Y
4.67%
RETURN ON EQUITY (ROE) AVG 5Y
11.22%
RETURN ON EQUITY (ROE) AVG 10Y
10.36%
RETURN ON EQUITY (ROE) AVG 15Y
8.10%
RETURN ON EQUITY (ROE) AVG 20Y
7.19%
CURRENT VS TTM AVG
-39.15%
CURRENT VS 3Y AVG
-38.76%
CURRENT VS 5Y AVG
-74.51%
CURRENT VS 10Y AVG
-72.39%
CURRENT VS 15Y AVG
-64.69%
CURRENT VS 20Y AVG
-60.24%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-73.74%
vs the sector median at left
The Cooper Companies, Inc.
Market Cap
$14.05B
Return on Equity (ROE)
2.86%
TTM Avg
4.70%
3Y Avg
4.67%
5Y Avg
11.22%
Market Cap
$14.92B
Return on Equity (ROE)
28.82%
TTM Avg
23.51%
3Y Avg
17.50%
5Y Avg
13.68%
Market Cap
$15.37B
Return on Equity (ROE)
-114.70%
TTM Avg
329.18%
3Y Avg
200.63%
5Y Avg
164.66%
Market Cap
$12.59B
Return on Equity (ROE)
-18.17%
TTM Avg
-12.46%
3Y Avg
-8.76%
5Y Avg
-1.37%
Market Cap
$12.58B
Return on Equity (ROE)
10.36%
TTM Avg
10.54%
3Y Avg
10.84%
5Y Avg
19.93%
Market Cap
$12.44B
Return on Equity (ROE)
3.35%
TTM Avg
3.59%
3Y Avg
3.35%
5Y Avg
7.68%
Market Cap
$15.94B
Return on Equity (ROE)
113.29%
TTM Avg
73.63%
3Y Avg
65.34%
5Y Avg
49.74%
Market Cap
$11.60B
Return on Equity (ROE)
23.25%
TTM Avg
25.41%
3Y Avg
19.99%
5Y Avg
14.02%
Market Cap
$11.58B
Return on Equity (ROE)
-6.28%
TTM Avg
-2.13%
3Y Avg
6.32%
5Y Avg
9.65%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| The Cooper Companies, Inc. (COO) | $14.05B | 2.86% | 4.70% | 4.67% | 11.22% |
| Solventum Corporation (SOLV)vs › | $14.92B | 28.82% | 23.51% | 17.50% | 13.68% |
| DaVita Inc. (DVA)vs › | $15.37B | -114.70% | 329.18% | 200.63% | 164.66% |
| Baxter International Inc. (BAX)vs › | $12.59B | -18.17% | -12.46% | -8.76% | -1.37% |
| Align Technology, Inc. (ALGN)vs › | $12.58B | 10.36% | 10.54% | 10.84% | 19.93% |
| Revvity, Inc. (RVTY)vs › | $12.44B | 3.35% | 3.59% | 3.35% | 7.68% |
| Medpace Holdings, Inc. (MEDP)vs › | $15.94B | 113.29% | 73.63% | 65.34% | 49.74% |
| Insulet Corp. (PODD)vs › | $11.60B | 23.25% | 25.41% | 19.99% | 14.02% |
| Charles River Laboratories International, Inc. (CRL)vs › | $11.58B | -6.28% | -2.13% | 6.32% | 9.65% |
| Bio-Techne Corporation (TECH)vs › | $11.28B | 5.25% | 5.98% | 10.62% | 11.34% |
ROE
2.9%
ROA
1.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-10-31 | 4.55% |
| 2024-10-31 | 4.85% |
| 2023-10-31 | 3.90% |
| 2022-10-31 | 5.38% |
| 2021-10-31 | 42.42% |
| 2020-10-31 | 6.23% |
| 2019-10-31 | 12.86% |
| 2018-10-31 | 4.23% |
| 2017-10-31 | 11.74% |
| 2016-10-31 | 10.16% |
| 2015-10-31 | 7.63% |
| 2014-10-31 | 10.50% |
| 2013-10-31 | 12.32% |
| 2012-10-31 | 11.33% |
| 2011-10-31 | 9.05% |
| 2010-10-31 | 6.77% |
| 2009-10-31 | 6.53% |
| 2008-10-31 | 4.62% |
| 2007-10-31 | -0.77% |
| 2006-10-31 | 4.80% |
| 2005-10-31 | 7.20% |
| 2004-10-31 | 17.06% |
| 2003-10-31 | 16.29% |
| 2002-10-31 | 15.69% |
| 2001-10-31 | 14.49% |
| 2000-10-31 | 14.60% |
| 1999-10-31 | 15.30% |
| 1998-10-31 | 27.39% |
| 1997-10-31 | 28.16% |
| 1996-10-31 | 108.50% |
